ASP Isotopes invests $5M in IsoBio for Series Seed-1 Preferred Stock

ASP Isotopes Inc.

ASP Isotopes acquired 2M shares of IsoBio Series Seed-1 Preferred at $2.50/share for $5M total.
IsoBio is a radiotherapeutic developer focused on antibody-isotope conjugates (AICs) for cancer.
IsoBio was co-founded by Bruce Turner, M.D., PhD, former Roche executive and co-leader of Immunome merger.
ASP Isotopes gets one board seat (CEO Paul Mann), veto rights over major actions, and antidilution protection.
Related parties: CEO Paul Mann and director Todd Wider hold IsoBio stock; both are parties to voting and ROFR agreements.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.